Immunome (IMNM) to Release Quarterly Earnings on Monday

Key Points

• Immunome is set to announce its Q2 2025 earnings on August 11th, with analysts anticipating losses of ($0.52) per share and revenues of $1.03 million.
• Last quarter, the company reported ($0.52) EPS, surpassing analyst expectations, and generated revenue of $2.93 million compared to the forecast of $0.46 million.
• Recent analyst ratings include a downgrade from "sell" to "hold" and a revised target price of $21.00 from Wedbush, reflecting a consensus target price of $23.33.

Immunome (NASDAQ:IMNM - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $1.03 million for the quarter.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. The company had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Price Performance

Shares of IMNM opened at $10.48 on Monday. Immunome has a one year low of $5.15 and a one year high of $16.73. The company has a 50-day moving average of $9.38 and a two-hundred day moving average of $8.89. The stock has a market cap of $911.45 million, a price-to-earnings ratio of -3.29 and a beta of 1.92.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Wedbush reiterated an "outperform" rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $23.33.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime bought 5,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was purchased at an average cost of $9.38 per share, for a total transaction of $46,900.00. Following the purchase, the director directly owned 36,415 shares in the company, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 8.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Immunome

An institutional investor recently raised its position in Immunome stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 44.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,821 shares of the company's stock after buying an additional 14,398 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of Immunome worth $316,000 as of its most recent SEC filing. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.